Herpes Zoster Pipeline Drugs and Companies Insight Report (2023): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Herpes Zoster pipeline constitutes 18+ key companies continuously working towards developing 20+ Herpes Zoster treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Herpes Zoster Overview
Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation of varicella-zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection with VZV before in life. VZV is explicitly a human virus that belongs to the α-herpes virus family. It is present worldwide and is highly contagious. More than 90% of adults in the United States acquired the disease in childhood, while the majority of children and young adults have been vaccinated with the live virus vaccine.

"Herpes Zoster Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Zoster Market.

The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Herpes Zoster Pipeline Report: https://www.delveinsight.com/report-store/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Herpes Zoster treatment therapies with a considerable amount of success over the years. Herpes Zoster Key players such as - CPL Biologics, EuBiologics, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc., Changchun BCHT Biotechnology, and others, are developing therapies for the Herpes Zoster treatment
• Herpes Zoster Emerging therapies such as - VZV Vaccine, Herpes Zoster vaccine, mRNA-1468 Moderna, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others are expected to have a significant impact on the Herpes Zoster market in the coming years.
• Changchun BCHT Biotechnology initiated a Phase III Multicenter, Randomized, Double blinded, Placebo-controlled Trial. The primary outcome was to evaluate the efficacy of the vaccine against herpes zoster 30 days after vaccination and the safety of the vaccine.
• In February 2022, Curevo Inc. initiated a randomized observer-blind, Phase II Study to assess the safety and immunogenicity of CRV-101 vaccine head-to-head with shingrix for the prevention of herpes zoster in adults aged 50 years and older. randomized 1:1:1 to CRV-101 Vaccine high antigen dose, CRV-101 Vaccine low antigen dose, or Shingrix. Both study vaccines, CRV-101 Vaccine and Shingrix will be administered by intramuscular injection on Month 0 and Month 2

Herpes Zoster Pipeline Therapeutics Assessment
• Herpes Zoster Assessment by Product Type
• Herpes Zoster By Stage and Product Type
• Herpes Zoster Assessment by Route of Administration
• Herpes Zoster By Stage and Route of Administration
• Herpes Zoster Assessment by Molecule Type
• Herpes Zoster by Stage and Molecule Type

DelveInsight's Herpes Zoster Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Herpes Zoster Drugs Under Different Phases of Clinical Development Include:
• VZV Vaccine: CPL Biologics
• Herpes Zoster vaccine: EuBiologics
• mRNA-1468 Moderna
• GLS5100: Gene One Life Science
• Z-1018 Dynavax Technologies Corporation
• EG-HZ: EyeGene
• CRV101: Curevo Inc.
• Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Get a Free Sample PDF Report to know more about Herpes Zoster Pipeline Assessment- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Zoster Pipeline Analysis:
The Herpes Zoster pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Herpes Zoster treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Zoster Treatment.
• Herpes Zoster key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Herpes Zoster Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Zoster market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Herpes Zoster product details are provided in the report. Download the Herpes Zoster pipeline report to learn more about the emerging Herpes Zoster therapies at:
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Zoster Pipeline Market Drivers
• Increasing awareness and high demand for shingles prevention
• Rising incidence of herpes zoster
• Increasing awareness and high demand for shingles prevention
• Favorable reimbursement and funding policies

Herpes Zoster Pipeline Market Barriers
• High cost of vaccines
• Lack of vaccine compliance and knowledge about Shingles prevention
• Logistical and storage barriers

Scope of Herpes Zoster Pipeline Drug Insight
• Coverage: Global
• Key Herpes Zoster Companies: CPL Biologics, EuBiologics, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc., Changchun BCHT Biotechnology, and others
• Key Herpes Zoster Therapies: VZV Vaccine, Herpes Zoster vaccine, mRNA-1468 Moderna, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others
• Herpes Zoster Therapeutic Assessment: Herpes Zoster current marketed and Herpes Zoster emerging therapies
• Herpes Zoster Market Dynamics: Herpes Zoster market drivers and Herpes Zoster market barriers

Request for Sample PDF Report for Herpes Zoster Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Herpes Zoster Report Introduction
2 Herpes Zoster Executive Summary
3 Herpes Zoster Overview
4 Herpes Zoster- Analytical Perspective In-depth Commercial Assessment
5 Herpes Zoster Pipeline Therapeutics
6 Herpes Zoster Late Stage Products (Phase II/III)
7 Herpes Zoster Mid Stage Products (Phase II)
8 Herpes Zoster Early Stage Products (Phase I)
9 Herpes Zoster Preclinical Stage Products
10 Herpes Zoster Therapeutics Assessment
11 Herpes Zoster Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Herpes Zoster Key Companies
14 Herpes Zoster Key Products
15 Herpes Zoster Unmet Needs
16 Herpes Zoster Market Drivers and Barriers
17 Herpes Zoster Future Perspectives and Conclusion
18 Herpes Zoster Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Herpes Zoster drugs and therapies- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Herpes Zoster Market https://www.delveinsight.com/report-store/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Herpes Zoster Epidemiology https://www.delveinsight.com/report-store/herpes-zoster-oticus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latetst Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.